Chemical Structure (Alendronate 01)
Alendronate
Product Images NDC 50090-3593
8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 50090-3593). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Alendronate 02)
A line graph depicting cumulative incidence (%) over time (months) comparing Alendronate Sodium and Placebo. The graph shows two lines, with the Alendronate Sodium line consistently lower than the Placebo line over a 36-month period.*
Figure 2 (Alendronate 03)
A bar graph comparing the mean percentage increase in bone mineral density (BMD) relative to placebo plus standard error (SE) at three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter, for two groups labeled USA and Multinational. The USA group shows higher increases across all sites compared to the Multinational group.*
Figure 3 (Alendronate 04)
Two line graphs displaying mean percent change in bone mineral density (BMD) from baseline over 36 months, comparing Alendronate Sodium 10 mg versus placebo. The left graph is labeled 'US Study' and the right 'Multinational Study.' Both show increasing BMD with Alendronate Sodium and near zero or negative change with placebo.*
Figure 4 (Alendronate 05)
A set of two bar charts comparing the change in bone mineral density (BMD) from baseline for Alendronate Sodium 5mg/day versus placebo in a 2-year and a 3-year study. Each chart displays mean percentage change in BMD with standard error bars at four anatomical sites: lumbar spine, femoral neck, trochanter, and total body.*
Figure 5 (Alendronate 06)
A bar chart comparing mean percentage increase in bone mineral density (BMD) relative to placebo with standard error (SE) at three anatomical sites: lumbar spine, femoral neck, and trochanter. The chart shows data for two groups labeled USA and Multinational, with the Multinational group demonstrating higher mean increases across all sites.*
Figure 6 (Alendronate 07)
A line graph showing mean percent change from baseline in serum alkaline phosphatase over time in months (0, 3, 6) for four groups: Placebo, Etidronate 400 mg/day, Alendronate Sodium 40 mg/day (multinational study), and Alendronate Sodium 40 mg/day (U.S. study). The values indicate a decrease in serum alkaline phosphatase for Etidronate and both Alendronate groups compared to placebo, with sample sizes listed for each group.*
Label Image (Lbl500903593)
Alendronate 35 mg tablet label from A-S Medication Solutions. The label indicates the product is to be taken once weekly, with storage instructions to keep at 68-77 degrees Fahrenheit. The pack count is 4 tablets. The label also includes an NDC number, lot number, and a QR code for dosage information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
